{"id":234,"date":"2022-08-16T10:00:00","date_gmt":"2022-08-16T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=234"},"modified":"2025-09-07T12:08:49","modified_gmt":"2025-09-07T12:08:49","slug":"china-bd-2022-jemincare-and-genentech-roche-enters-a-650-million-usd-license-on-ar-degrader-jmkx002992-rg6537-gdc-2992","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2022\/234.html","title":{"rendered":"[China BD 2022] Jemincare and Genentech (Roche) enters a 650 million USD license on AR degrader JMKX002992 (RG6537, GDC-2992)"},"content":{"rendered":"\n

Announced Date: 2022-08-05 (August 18, 2025)<\/p>\n\n\n\n

Asset Name: JMKX002992 (RG6537, GDC-2992)<\/p>\n\n\n\n

Licensor: Shanghai Jemincare Pharmaceutical (China)<\/p>\n\n\n\n

Licensee (Buyer): Genentech, member of Roche Group<\/p>\n\n\n\n

.<\/p>\n\n\n\n

Asset Modality: Small Molecule, oral degrader<\/p>\n\n\n\n

Asset Target: Androgen receptor (AR) degrader<\/p>\n\n\n\n

Potential Indication: prostate cancer<\/p>\n\n\n\n

Current Stage: <\/p>\n\n\n\n

.<\/p>\n\n\n\n

Scope of Authority:<\/p>\n\n\n\n

Jemincare will grant Genentech the exclusive license to develop and commercialize the degrader worldwide, and will be fully responsible for the development and commercialization costs.<\/p>\n\n\n\n

.<\/p>\n\n\n\n

Payment Detail:<\/p>\n\n\n\n

Jemincare will receive\uff1a<\/p>\n\n\n\n

Upfront payment of\u00a0$60 million,<\/p>\n\n\n\n

Regulatory and sales milestone payments up to \u00a0$590 million.<\/p>\n\n\n\n

Tiered royalties on net sales.<\/p>\n\n\n\n

.<\/p>\n\n\n\n

Link:<\/p>\n\n\n\n

Jemincare Announces Exclusive License Agreement with Genentech to Develop and Commercialize Novel Oral Androgen Receptor Degrader<\/p>\n\n\n\n

https:\/\/www.jemincare.com\/news\/detail.html?id=94<\/a><\/p>\n\n\n\n

.<\/p>\n\n\n\n

Note:<\/p>\n\n\n\n

Chinese Name of Jemincare \u6d4e\u6c11\u53ef\u4fe1<\/p>\n\n\n\n

Chinese Name of Shanghai Jemincare Pharmaceutical \u4e0a\u6d77\u6d4e\u715c<\/p>\n","protected":false},"excerpt":{"rendered":"

Announced Date: 2022-08-05 (August 18, 2025) Asset Name: JMKX002992 (RG6537, GDC-2992) Licensor: Shanghai Jemincare Pharmaceutical (China) … [China BD 2022] Jemincare and Genentech (Roche) enters a 650 million USD license on AR degrader JMKX002992 (RG6537, GDC-2992)<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-234","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/234","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=234"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/234\/revisions"}],"predecessor-version":[{"id":236,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/234\/revisions\/236"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=234"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=234"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=234"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}